Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $4.25M fell 52.3% year over year, behind the -41.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -52.3% toward the trailing-twelve-month pace of -41.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 26.23M USD
- Year-over-year change
- -30.3%
- 4-year CAGR
- +25.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.23M | -30.3% |
| FY2024 | 2024-12-31 | 37.63M | -15.4% |
| FY2023 | 2023-12-31 | 44.48M | +96.8% |
| FY2022 | 2022-12-31 | 22.6M | +116.5% |
| FY2021 | 2021-12-31 | 10.44M | — |
Stock-Based Compensation vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 stock-based compensation of $21.58M is the largest of the 10 companies compared; the peer median is $7.81M.
- Its year-over-year change of -41.5% is the 7th highest of 10, against a peer median of -16.6%.
- Over three fiscal years its annual growth of +5.1% compares with a peer median of -9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.58M | -41.5% | +5.1% | — | |
| LTM Mar 2026 | $14.24M | -76.6% | -23.8% | — | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.03M | -58.5% | -18.9% | 10.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $9.87M | -8.9% | +0.8% | 138.2% |
| LTM Mar 2026 | $7.81M | -26.4% | +28.7% | — | |
| LTM Mar 2026 | $7.45M | -5.5% | -9.2% | 5559.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $6.36M | -16.6% | +1.2% | — |
| LTM Mar 2026 | $5.41M | +63.4% | +174.5% | 68.1% | |
| LTM Mar 2026 | $2.41M | -6.9% | -9.8% | 33.9% | |
| Peer median (excluding PLRX) | $7.81M | -16.6% | -9.2% | 51.0% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Depreciation & Amortization | 1.54M | 1.82M | 1.84M | 2.13M | 1.7M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.44M | 22.6M | 44.48M | 37.63M | 26.23M |
| Change in Working Capital | 6.92M | 4.22M | 1.25M | 9.09M | (15.94M) |
| Accounts Receivables | 7.28M | 15K | 1.98M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 891K | (1.35M) | 2.97M | 1.43M | (5.48M) |
| Other Working Capital | (1.26M) | 5.55M | (3.7M) | 7.66M | (10.46M) |
| Other Non-Cash Items | 2.93M | 52K | (2.6M) | 5.96M | 9.02M |
| Operating Cash Flow | (75.44M) | (94.63M) | (116.36M) | (155.5M) | (128.34M) |
| Capital Expenditures | (1.95M) | (1.76M) | (921K) | (3.85M) | (374K) |
| Acquisitions (Net) | (75.65M) | 148.44M | 0 | 0 | 155K |
| Purchases of Investments | (219.89M) | (325.72M) | (583.07M) | (211.29M) | (203.4M) |
| Sales of Investments | 295.54M | 177.27M | 456.98M | 355.47M | 337.91M |
| Other Investing Activities | 75.65M | (148.44M) | 0 | 0 | 0 |
| Investing Cash Flow | 73.7M | (150.2M) | (127.01M) | 140.34M | 134.29M |
| Debt Repayment | 0 | 10M | 0 | 19.91M | (32.27M) |
| Common Stock Issued | 2.98M | 215.64M | 275.25M | 3.21M | 570K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (457K) | 1.21M | 5M | 0 | 0 |
| Financing Cash Flow | 2.53M | 226.85M | 274.41M | 23.12M | (31.7M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 783K | (17.98M) | 31.03M | 7.95M | (25.74M) |
| Free Cash Flow | (77.4M) | (96.39M) | (117.28M) | (159.35M) | (128.71M) |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.